Dermatology Times

A leading news resource serving dermatology clinicians.

[Dermatology Times @DermTimesNow]

💡 EXPERT INSIGHTS: Undertreating severe atopic dermatitis in children can have consequences that extend far beyond the skin.

Read more: https://t.co/m9YiB874wE

#AtopicDermatitis #PediatricDermatology #Eczema #Dermatology

[Dermatology Times @DermTimesNow]

🇺🇸 VETERANS DAY: Today, we honor the men and women who have served our country and recognize the lasting health challenges some veterans continue to face long after their service.

https://t.co/APoYBiCjGn

#VeteransDay #VeteransHealth #AgentOrange #Melanoma #Dermatology

[Dermatology Times @DermTimesNow]

📈 NEW DATA: Brepocitinib achieved complete skin clearance in 69% of patients with cutaneous sarcoidosis, highlighting a potential new treatment approach for this difficult-to-manage condition.

https://t.co/FyjFnJGUjf

#Brepocitinib #CutaneousSarcoidosis #JAKInhibitors

[Dermatology Times @DermTimesNow]

61% complete skin clearance with ORKA-001. Zasocitinib outperforming deucravacitinib head to head.
October's top psoriasis, HS, and eczema stories in one recap ↓
https://t.co/7NQsud1nOc

[Dermatology Times @DermTimesNow]

📈 NEW DATA: Litifilimab demonstrated improvements in clinician- and patient-reported skin symptoms through 52 weeks in patients with cutaneous lupus erythematosus (CLE).

Read more: https://t.co/Hkyrc5Vpfi

#Litifilimab #CutaneousLupus #Lupus #Dermatology

[Dermatology Times @DermTimesNow]

📈 NEW DATA: How do emerging oral psoriasis therapies compare when it comes to complete skin clearance?

Read more: https://t.co/MC8RSJVzae

#Psoriasis #OralTherapies #PASI100 #Dermatology

[Dermatology Times @DermTimesNow]

📈 NEW DATA: Veradermics reported sustained hair growth through 1 year with investigational oral VDPHL01 in patients with androgenetic alopecia.

Read more: https://t.co/T5XVm3YXER

#VDPHL01 #AndrogeneticAlopecia #HairLoss #Dermatology

[Dermatology Times @DermTimesNow]

📈 NEW DATA: Bimekizumab demonstrated sustained joint responses through week 24 in patients with active psoriatic arthritis (PsA).

Read more: https://t.co/dyN3gmtBXq

#Bimekizumab #PsoriaticArthritis #Psoriasis #Dermatology

[Dermatology Times @DermTimesNow]

Join the community: https://t.co/AxYsuXdsuX

[Dermatology Times @DermTimesNow]

Your patients get your expertise. Your peers deserve it, too. Practicing dermatologist, NP, or PA? Share what you know as a roundtable moderator, podcast guest, writer, or on-camera expert.

Join the community: https://t.co/RfUqeKqA8g

[Dermatology Times @DermTimesNow]

Remibrutinib (Rhapsido) is now the first FDA-approved treatment for symptomatic dermographism.
RemIND: 29.3% complete hive response vs 14.0% with placebo at week 12.
Clinician FAQ ↓
https://t.co/YM8UbYXa4l

[Dermatology Times @DermTimesNow]

🔔👥 CONFERENCE COVERAGE: Today, Dermatology Times is on-site in Philadelphia with Joel Gelfand, MD, MSCE, for DPEC: Dermatology in Pharma Educational Collaborative!

#DPEC2026 #DermatologyTimes #Dermatology #DermatologyResearch

[Dermatology Times @DermTimesNow]

📖 BETWEEN THE LINES: Remibrutinib is reshaping the treatment landscape for chronic inducible urticaria (CIndU).

Read more: https://t.co/Mw7LUAdWpr

#BetweenTheLines #Remibrutinib #ChronicInducibleUrticaria #Dermatology

[Dermatology Times @DermTimesNow]

✍⏳ THE PRACTICE BRIEF: New treatment options are expanding dermatologic care, but access barriers and evolving clinical guidance continue to shape everyday practice.

🔗 Read more: https://t.co/sZ79cHT1xT

#ThePracticeBrief #NPPAConnect #AdvancedPractice #Dermatology

[Dermatology Times @DermTimesNow]

💡 NPPA CONNECT: Nurse practitioners are making an impact far beyond the exam room. In recognition of National Nurse Practitioner Week, explore the growing influence of NPs across the profession.

https://t.co/O62TJlXQRY

#NPWeek #NursePractitioners #NPPAConnect #AdvancedPractice

[Dermatology Times @DermTimesNow]

Remibrutinib (Rhapsido) is now the first FDA-approved treatment for symptomatic dermographism.

RemIND: 29.3% complete hive response vs 14.0% with placebo at week 12.
Clinician FAQ ↓
https://t.co/IDWHdt3iTG

[Dermatology Times @DermTimesNow]

🚨 NEW TODAY: The American Academy of Dermatology Association (AADA) is warning of a potential 6% Medicare payment cut for dermatologists in 2027.

Read more: https://t.co/fNjdqhuK3M

#Medicare #Dermatology #HealthCarePolicy #PhysicianReimbursement

[Dermatology Times @DermTimesNow]

Lisa Swanson, MD, joins host Andrew Krakowski, MD, to discuss the often-overlooked impact of psoriasis on children’s quality of life in this episode of Don’t Be Rash, supported by Arcutis.

Watch the full episode here:

#PediatricPsoriasis #DontBeRash

[Dermatology Times @DermTimesNow]

#Sponsored by Sun Pharmaceutical Industries, Inc.

Treatment decisions for locally advanced basal cell carcinoma often extend beyond tumor removal alone. Cosmetic concerns, surgical fatigue, and recovery burden may all influence patient care. https://t.co/6cioABr5X6

[Dermatology Times @DermTimesNow]

Remibrutinib (Rhapsido) is now the first FDA-approved treatment for symptomatic dermographism.
RemIND: 29.3% complete hive response vs 14.0% with placebo at week 12.
Check out our clinician FAQ ↓
Swipe through →
https://t.co/JcN9zRSkCE
#Dermatology #Urticaria